This book offers a comprehensive review of recent advances in cancer immunotherapy and
explores the value and limitations of the most effective current therapeutic strategies and
emerging treatment modalities. It discusses in detail the successes achieved using monoclonal
antibodies (mAbs) including developments with regard to conjugated mAbs and also bispecific
mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances
toward personalized immunotherapy focusing on the effectiveness of adoptive cell therapy using
genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and
chimeric antigen receptors as well as the role of tailored vaccines based on the patient's
cancer mutanome. Further it describes the impressive therapeutic results recently achieved
with checkpoint inhibitors and analyzes novel strategies to modulate the immunosuppressive
tumor microenvironment. Written by leading international experts and providing up-to-date
information on emerging strategies such as oncolytic virus-based therapy epigenetic therapy
and combination therapy the book appeals to all those with an interest in immunotherapy as it
comes of age.
